XUANZHUBIO-B Shares Surge as Three Key Products Advance to Commercial Stage

Stock News06-04

Shares of XUANZHUBIO-B (02575) rose more than 5% in trading. At the time of writing, the stock was up 5.17% to HK$17.29, with a turnover of HK$46.84 million.

Key Drivers Behind the Move

A recent research report highlighted expectations for the company's revenue to grow steadily as its commercialization efforts accelerate. The firm has now moved three of its core product candidates into the commercial phase.

The drug anaprazol has been launched for the treatment of duodenal ulcer, with its applications for eradicating Helicobacter pylori and treating reflux esophagitis currently under expansion. Another drug, piroxiclib, is described as the only CDK4/6 inhibitor approved for monotherapy in later-line treatment of HR+/HER2- advanced breast cancer. A third product, diroac, has demonstrated a higher objective response rate in patients with brain metastases.

International Expansion Efforts

Furthermore, the company's core products have begun expanding internationally. In April 2026, the company entered into a licensing and supply agreement with Boston Oncology CGT for piroxiclib and diroac in the Middle East and North Africa region. This deal provides XUANZHUBIO-B with an upfront payment, potential milestone payments exceeding US$100 million, and sales royalties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173805012?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 14:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173805012","market":"us","top_or_hot":-1,"title":"XUANZHUBIO-B Shares Surge as Three Key Products Advance to Commercial Stage","media":"Stock News","content":"<p>Shares of <b>XUANZHUBIO-B</b> (<b>02575</b>) rose more than 5% in trading. At the time of writing, the stock was up 5.17% to HK$17.29, with a turnover of HK$46.84 million.<br><br>\n<b>Key Drivers Behind the Move</b><br><br>\nA recent research report highlighted expectations for the company's revenue to grow steadily as its commercialization efforts accelerate. The firm has now moved three of its core product candidates into the commercial phase.<br><br>\nThe drug anaprazol has been launched for the treatment of duodenal ulcer, with its applications for eradicating Helicobacter pylori and treating reflux esophagitis currently under expansion. Another drug, piroxiclib, is described as the only CDK4/6 inhibitor approved for monotherapy in later-line treatment of HR+/HER2- advanced breast cancer. A third product, diroac, has demonstrated a higher objective response rate in patients with brain metastases.<br><br>\n<b>International Expansion Efforts</b><br><br>\nFurthermore, the company's core products have begun expanding internationally. In April 2026, the company entered into a licensing and supply agreement with Boston Oncology CGT for piroxiclib and diroac in the Middle East and North Africa region. This deal provides <b>XUANZHUBIO-B</b> with an upfront payment, potential milestone payments exceeding US$100 million, and sales royalties.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XUANZHUBIO-B Shares Surge as Three Key Products Advance to Commercial Stage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXUANZHUBIO-B Shares Surge as Three Key Products Advance to Commercial Stage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-04 14:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>XUANZHUBIO-B</b> (<b>02575</b>) rose more than 5% in trading. At the time of writing, the stock was up 5.17% to HK$17.29, with a turnover of HK$46.84 million.<br><br>\n<b>Key Drivers Behind the Move</b><br><br>\nA recent research report highlighted expectations for the company's revenue to grow steadily as its commercialization efforts accelerate. The firm has now moved three of its core product candidates into the commercial phase.<br><br>\nThe drug anaprazol has been launched for the treatment of duodenal ulcer, with its applications for eradicating Helicobacter pylori and treating reflux esophagitis currently under expansion. Another drug, piroxiclib, is described as the only CDK4/6 inhibitor approved for monotherapy in later-line treatment of HR+/HER2- advanced breast cancer. A third product, diroac, has demonstrated a higher objective response rate in patients with brain metastases.<br><br>\n<b>International Expansion Efforts</b><br><br>\nFurthermore, the company's core products have begun expanding internationally. In April 2026, the company entered into a licensing and supply agreement with Boston Oncology CGT for piroxiclib and diroac in the Middle East and North Africa region. This deal provides <b>XUANZHUBIO-B</b> with an upfront payment, potential milestone payments exceeding US$100 million, and sales royalties.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1173805012","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173805012","pubTimestamp":1780555828,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of XUANZHUBIO-B (02575) rose more than 5% in trading. At the time of writing, the stock was up 5.17% to HK$17.29, with a turnover of HK$46.84 million. Key Drivers Behind the Move A recent...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","BK1191":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","02575":"轩竹生物-B"},"translate_title":"轩竹生物-B股大涨，三大关键产品进入商业化阶段","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1,"VXUS":1},"content_text":"Shares of XUANZHUBIO-B (02575) rose more than 5% in trading. At the time of writing, the stock was up 5.17% to HK$17.29, with a turnover of HK$46.84 million.\nKey Drivers Behind the Move\nA recent research report highlighted expectations for the company's revenue to grow steadily as its commercialization efforts accelerate. The firm has now moved three of its core product candidates into the commercial phase.\nThe drug anaprazol has been launched for the treatment of duodenal ulcer, with its applications for eradicating Helicobacter pylori and treating reflux esophagitis currently under expansion. Another drug, piroxiclib, is described as the only CDK4/6 inhibitor approved for monotherapy in later-line treatment of HR+/HER2- advanced breast cancer. A third product, diroac, has demonstrated a higher objective response rate in patients with brain metastases.\nInternational Expansion Efforts\nFurthermore, the company's core products have begun expanding internationally. In April 2026, the company entered into a licensing and supply agreement with Boston Oncology CGT for piroxiclib and diroac in the Middle East and North Africa region. This deal provides XUANZHUBIO-B with an upfront payment, potential milestone payments exceeding US$100 million, and sales royalties.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173805012","isCrawlerRequest":true}